Mutations tested at these time-points were in AML-specific genes (e.g. NPM1, FLT3) as well as genes commonly associated with mutations in CHIP (e.g. IDH1/2, DNMT3A, and TP53). This evidence concerns the gene FLT3 and acute myeloid leukemia.